Consultancy.uk featured Stratence Partners following EPA Amsterdam 2026, highlighting how healthcare organizations can transform pricing pressure, fragmented data, and Gross-to-Net complexity into structured, AI-Powered commercial decision systems.

MFN is reshaping global pharma pricing. The real challenge is not price reduction, but controlling how value propagates across markets. This paper explains how leading organizations are redesigning their commercial systems to protect global asset value.

Pharma is not facing a pricing problem, but a fragmented commercial system. Discover why CEOs must now lead Commercial Transformation as an integrated operating model.

Gross-to-Net is no longer a reporting exercise. Discover how leading organizations turn pricing complexity into sustainable revenue through structured governance and AI-powered commercial systems.

At EPA Amsterdam 2026, Fernando Ventureira, CEO of Stratence Partners, presented two sessions addressing critical challenges for pharmaceutical and MedTech companies: mastering Gross to Net complexity and embedding AI into commercial decision making. This article summarizes the key insights on how organizations can transform pricing, access, and commercial execution into a unified performance system.

Pharma transformations fail when operating models don’t evolve. Learn how Stratence Partners helps organizations embed change through governance, processes, and capability building.

Pharma generates data everywhere, but few companies turn it into actionable intelligence. Discover how Stratence Partners helps transform information into measurable strategic advantage.

Pharma strategy must evolve to stay ahead of innovation, regulation, and pricing challenges. Discover how Stratence Partners helps global pharma companies align vision, Market Access, and execution for measurable results.

Welcome Aleksandar Ruzicic as Stratence Partners' new SVP! Over 30 years of healthcare consulting expertise. Exciting times ahead!